立体定向放射外科治疗颅内表皮样肿瘤的作用:系统综述评估其安全性、疗效与并发症特征
本系统综述遵循PRISMA指南检索多个数据库,纳入良性表皮样肿瘤与恶性转化表皮样肿瘤的放射外科研究。良性组25例(65.7%)接受原发性立体定向放射外科,9.5%出现短暂颅神经缺损,随访期间良性病例无复发;恶性转化组总生存期为GKRS后6至60个月,末次随访时50%患者存活。作者认为立体定向放射外科可能是有前景的治疗选择。
要点
- 良性表皮样肿瘤放射外科后随访33.7至60个月,末次随访无复发病例报告
- 9.5%患者出现短暂颅神经缺损,无持久性放射不良反应
- 恶性转化组GKRS后总生存期6至60个月,末次随访50%患者存活
核心结论
- 立体定向放射外科可能对传统上为良性且放射抵抗的表皮样肿瘤是有前景的治疗选择,可能对疾病自然史产生有意义的改变。
- 对于恶性转化表皮样肿瘤患者,立体定向放射外科是有价值的辅助技术。
研究设计与样本
- 遵循PRISMA指南,对PubMed、Embase、Scopus和Web of Science数据库已发表的英文文献进行全面检索。
- 纳入接受放射外科治疗的良性表皮样肿瘤及恶性转化表皮样肿瘤研究,共纳入良性表皮样肿瘤6项研究、恶性转化表皮样肿瘤8项研究。
- 检索共发现403篇文章。
- 纳入标准为至少报告一项感兴趣结局:局部控制、无进展生存、症状性毒性、疾病进展、再治疗、总生存和病因特异性死亡。
主要发现
- 25例(65.7%)患者接受原发性立体定向放射外科治疗。
- 27例患者表现为颅神经功能亢进综合征,其中77.7%获得完全改善。
- 总体中位年龄为46.7岁(范围22至67岁),良性表皮样肿瘤中位肿瘤体积范围为0.38至6.2cc。
- 6例出现体积缩小,2例出现进展,其余表皮样肿瘤保持稳定。
- 平均随访时长为33.7至60个月,良性表皮样肿瘤病例在末次随访时均未报告复发;9.5%患者出现短暂颅神经缺损,无持久性放射不良反应。
临床怎么用
- 作者认为立体定向放射外科可能是有前景的治疗选择,可能对传统上为良性且放射抵抗的表皮样肿瘤的自然史产生有意义的改变。
- 作者认为对于恶性转化表皮样肿瘤患者,立体定向放射外科是有价值的辅助技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Even a gross total resection of a benign epidermoid tumor (ET) carries a high risk of recurrence. The management strategy mostly involves redo surgical excision but at a significant cost of morbidity and mortality. The role of adjuvant radiation therapies in this scenario is still undefined. OBJECTIVE: To evaluate the feasibility, safety, efficacy, and complication profile of radiosurgery as a standalone or adjuvant therapy for intracranial epidermoid in the published literature. METHODOLOGY: Following PRISMA guidelines, a comprehensive search of the databases PubMed, Embase, Scopus, and Web of Science in published English language was conducted. We included studies with radiosurgery for benign ET and in patients with malignant transformation of ET (MTET). All studies were evaluated for tumor characteristics, pattern of treatment, dosimetric profile, outcome, and complications. We included all studies with at least one outcome of interest i.e. local control (LC); progression-free survival (PFS); symptomatic toxicity; disease progression; retreatment; and overall survival (OS); and cause-specific mortality. RESULTS: The search revealed 403 articles, of which 6 and 8 studies with patients of benign ET and MTET respectively were included. 25 (65.7%) patients received primary SRS. 27 patients presented with hyperactive cranial nerve syndromes; 77.7% gained complete improvement. The overall median age was 46.7 years (22-67) and the median tumor volume ranged from 0.38 to 6.2cc in benign ET. Volumetric reduction was seen in 6 cases; progression was seen in 2 cases while ET remained stable in the rest. Mean follow-up duration ranged from 33.7 to 60 months, and no recurrence was reported at the latest follow-up in any case of benign ET. 9.5% of patients suffered from transient cranial nerve deficits with no prolonged adverse radiation effect. OS in the MTET group was 6 to 60 months following GKRS with 50% of patients alive at the latest follow-up. CONCLUSION: SRS may be a promising treatment option for a conventionally benign and radioresistant ET making a meaningful change in the natural history of the disease. It is a valuable adjuvant technique in patients with MTET.
引用
- Verma O, Mishra S, Tripathi M, et al. Role of stereotactic radiosurgery for intracranial epidermoid tumors: a systematic review to assess its safety, efficacy, and complication profile. J Neurooncol. 2025. PMID: 39825145. doi:10.1007/s11060-024-04901-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。